OncoMatch/Clinical Trials/NCT06208150
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Is NCT06208150 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for multiple myeloma.
Treatment: Talquetamab · Pomalidomide · Teclistamab · Elotuzumab · Dexamethasone · Bortezomib — The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD38 antibody
Participants...who have received an anti-CD38 antibody
Must have received: immunomodulatory agent (lenalidomide)
Participants...who have received...lenalidomide
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Fresno · Clovis, California
- UCLA · Santa Monica, California
- Yale University School Of Medicine · New Haven, Connecticut
- Medical Oncology Hematology Consultants, PA · Newark, Delaware
- Memorial Healthcare System · Hollywood, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify